SCHEMBL648089

SCHEMBL648089

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc(F)c(Br)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.47
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 2/20 0.39
CRHR1 P34998 2/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HSD11B1 P28845 2/20 0.34
PDE4B Q07343 2/20 0.34
NR1H3 Q13133 1/20 0.33
HTT P42858 1/20 0.33
BCHE P06276 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648706 0.94 C5AR1 (0.46) C5AR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5136200 0.93 C5AR1 (0.43) C5AR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5134962 0.91 C5AR1 (0.48) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL650473 0.91 C5AR1 (0.41) C5AR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5134954 0.89 C5AR1 (0.43) C5AR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL652238 0.89 C5AR1 (0.64) C5AR1TSHRKDM4EALDH1A1HSD17B10
SCHEMBL648503 0.89 C5AR1 (0.47) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL649437 0.88 C5AR1 (0.46) C5AR1TSHRCRHR1KDM4EALDH1A1
SCHEMBL647516 0.87 C5AR1 (0.43) C5AR1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL5072370 0.87 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed